Don’t Miss the 2015 Business of Personalized Medicine Summit: Breaking Through to Business Solutions

 

Just as with patient treatments, one size does not fit all when it comes to companies involved in personalized medicine. Each is unique in its mission, culture, and capabilities, and so it should come as no surprise that each demands a distinct business strategy that can evolve alongside the industry. The 2015 BPM Summit is centered around helping attendees build just that — a successful, sustainable business model that allows them to realize the promise of personalized medicine.

 

Co-hosted by Foley & Lardner LLP, the Personalized Medicine Coalition, AmerisourceBergen, and the California Life Sciences Association, this one-day, one-of-a-kind thought leadership and networking forum features an agenda focused on the critical business questions, issues, and opportunities related to funding, research and development, public policy and regulation, technology, and more. Through fresh discussions with key opinion leaders and each other, attendees will collect insights and arrive at solutions that will drive their individual growth and performance as well as impact the overall future of health care.

 

 

FEATURED TOPICS

WHO SHOULD ATTEND

  • Financing & Venture Capital:
    How investments, partnerships, and other transactions are impacting the business of personalized medicine


  • Payment:
    Strategies for identifying your target market, collecting evidence, and getting paid

  • FDA/Regulatory:
    The FDA’s proposed oversight of LDT’s, Obama’s Precision Medicine Initiative, and what to expect in the future as a result

  • Big Pharma:
    A look at the industry’s involvement and investment in personalized medicine

  • Intellectual Property:
    High-profile cases with significant implications in the personalized medicine space both at the R&D stage and downstream

  • Big Data:
    Driving development through complex bioinformatics and collaborative results analysis, plus a look at cybersecurity implications

  • Disruptive Innovation:
    How personalized medicine is being reshaped through innovative business models, technology applications, and information management

  • Clinical Adoption:
    Barriers to and solutions for effective understanding, acceptance, integration, and knowledge sharing throughout the personalized medicine life cycle 

  • Business, legal, and health care professionals interested in industry leaders’ real-world experience on the current state of personalized medicine and where growth and opportunity exist

  • Business, legal, and health care professionals interested in discussions regarding the regulatory framework for diagnostics and targeted therapies

  • Executives and entrepreneurs interested in hearing diverse perspectives on both the development and delivery of personalized medicine therapies

  • Payors interested in current status and future possibilities regarding reimbursement of personalized medicine technologies

  • Corporate counsel in life sciences and health care provider organizations

  • Health care professionals working in the field of personalized medicine

  • Health care and life sciences investors

  • Researchers and academic personnel

  • Non-profit organizations